|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
IL316257A
(en)
|
2017-12-22 |
2024-12-01 |
Fate Therapeutics Inc |
Enhanced immune effector cells and use thereof
|
|
EP3749685A4
(en)
|
2018-02-09 |
2021-12-22 |
National University of Singapore |
ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
|
|
JP7334985B2
(ja)
|
2018-04-02 |
2023-08-29 |
ナショナル ユニヴァーシティー オブ シンガポール |
免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
|
|
US12378572B2
(en)
|
2018-09-07 |
2025-08-05 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
PE20211959A1
(es)
*
|
2019-02-15 |
2021-09-30 |
Editas Medicine Inc |
Celulas asesinas naturales (nk) modificadas para inmunoterapia
|
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
|
|
KR20210139472A
(ko)
*
|
2019-04-11 |
2021-11-22 |
페이트 세러퓨틱스, 인코포레이티드 |
조작된 iPSC 및 면역 효과기 세포에서의 CD3 재구성
|
|
CN114258429A
(zh)
*
|
2019-07-17 |
2022-03-29 |
菲特治疗公司 |
免疫效应细胞工程化和其用途
|
|
AU2020315213A1
(en)
*
|
2019-07-17 |
2022-02-03 |
National University Of Singapore |
Functional binders synthesized and secreted by immune cells
|
|
PH12022550542A1
(en)
|
2019-09-05 |
2023-03-20 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
MX2022003414A
(es)
*
|
2019-09-25 |
2022-04-18 |
Fate Therapeutics Inc |
Celulas efectoras con multiples objetivos y uso de las mismas.
|
|
EP4041759A4
(en)
*
|
2019-10-07 |
2023-12-20 |
Fate Therapeutics, Inc. |
IMPROVED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL CULTURE AND USE THEREOF
|
|
AU2020364157A1
(en)
*
|
2019-10-09 |
2022-04-14 |
Bluerock Therapeutics Lp |
Cells with sustained transgene expression
|
|
EP4045539A4
(en)
*
|
2019-10-17 |
2024-03-13 |
Fate Therapeutics, Inc. |
Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
|
|
US20230016034A1
(en)
*
|
2019-12-06 |
2023-01-19 |
Fate Therapeutics, Inc. |
ENHANCEMENT OF iPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDS
|
|
EP3858999A1
(en)
*
|
2020-01-30 |
2021-08-04 |
Aelian Biotechnology GmbH |
Safe harbor loci
|
|
CN111269326A
(zh)
*
|
2020-02-28 |
2020-06-12 |
南京北恒生物科技有限公司 |
新型嵌合抗原受体及其用途
|
|
TW202206460A
(zh)
*
|
2020-04-24 |
2022-02-16 |
荷蘭商美勒斯公司 |
使用結合lgr5及egfr之抗體的癌症治療
|
|
CN116018158A
(zh)
*
|
2020-04-30 |
2023-04-25 |
转化基因组学研究所 |
新抗原知情的肿瘤浸润性淋巴细胞癌免疫疗法
|
|
CN113801238A
(zh)
*
|
2020-06-11 |
2021-12-17 |
南京北恒生物科技有限公司 |
表达nk抑制性分子的工程化免疫细胞及其用途
|
|
BR112022025806A2
(pt)
*
|
2020-06-19 |
2023-03-07 |
Fate Therapeutics Inc |
Combinação de tipos de células efetoras derivadas de ipsc para uso em imunoterapia
|
|
WO2022007796A1
(zh)
*
|
2020-07-06 |
2022-01-13 |
上海鑫湾生物科技有限公司 |
共表达IL-21和hrCD16嵌合受体的免疫细胞及其应用
|
|
EP4185616A1
(en)
*
|
2020-07-24 |
2023-05-31 |
Cellectis S.A. |
T-cells expressing immune cell engagers in allogenic settings
|
|
CN114276996A
(zh)
*
|
2020-09-28 |
2022-04-05 |
未来智人再生医学研究院(广州)有限公司 |
一种表达pd-1/pd-l1阻断物的多能干细胞衍生物及应用
|
|
US20230364137A1
(en)
*
|
2020-09-30 |
2023-11-16 |
Vor Biopharma Inc. |
Chimeric antigen receptor expression systems
|
|
IL301983A
(en)
*
|
2020-10-09 |
2023-06-01 |
Fate Therapeutics Inc |
Transgenic induced pluripotent stem cells and effector carrier cells of the immune system
|
|
US20230398215A1
(en)
*
|
2020-10-28 |
2023-12-14 |
Sri International |
Genetically engineered antigen-specific natural killer cells for in situ synthesis of proteins
|
|
CN114507643A
(zh)
*
|
2020-10-29 |
2022-05-17 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-2的多能干细胞衍生物及应用
|
|
CN114426953A
(zh)
*
|
2020-10-29 |
2022-05-03 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-12的多能干细胞衍生物及应用
|
|
CN114525254A
(zh)
*
|
2020-10-30 |
2022-05-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达fgf-21的多能干细胞或其衍生物及应用
|
|
CN114517184A
(zh)
*
|
2020-10-30 |
2022-05-20 |
未来智人再生医学研究院(广州)有限公司 |
一种表达adipsin的多能干细胞或其衍生物及应用
|
|
CN114457025A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达btla阻断物的多能干细胞或其衍生物及应用
|
|
CN114457028A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达cd38抗体的多能干细胞及其衍生物与应用
|
|
CN114457031A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达b7-h5阻断物的多能干细胞或其衍生物及应用
|
|
CN114457022A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达ox40激活型抗体的多能干细胞及其衍生物与应用
|
|
CN114525258A
(zh)
*
|
2020-10-30 |
2022-05-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达pcsk9阻断物的多能干细胞或其衍生物及应用
|
|
WO2022095902A1
(en)
*
|
2020-11-03 |
2022-05-12 |
Hangzhou Qihan Biotechnology Co., Ltd. |
Systems and methods for enhanced immunotherapies
|
|
CN114525259B
(zh)
*
|
2020-11-03 |
2025-02-14 |
南京北恒生物科技有限公司 |
靶向cd7的嵌合抗原受体及其用途
|
|
AU2021372975A1
(en)
*
|
2020-11-04 |
2023-06-15 |
Fate Therapeutics, Inc. |
Engineered ipsc and persistent immune effector cells
|
|
EP4240832A4
(en)
*
|
2020-11-04 |
2025-01-01 |
Fate Therapeutics, Inc. |
Engineered ipsc and immune effector cells for heterogenous tumor control
|
|
US11459372B2
(en)
|
2020-11-30 |
2022-10-04 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
KR20230118887A
(ko)
|
2020-12-03 |
2023-08-14 |
센츄리 쎄라퓨틱스 인코포레이티드 |
유전자 조작 세포 및 이의 용도
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
CN114645018A
(zh)
*
|
2020-12-18 |
2022-06-21 |
未来智人再生医学研究院(广州)有限公司 |
一种表达cd38靶向抑制因子的多能干细胞及其衍生物与应用
|
|
CN114645020A
(zh)
*
|
2020-12-21 |
2022-06-21 |
未来智人再生医学研究院(广州)有限公司 |
一种表达靶向nr4a1抑制因子的多能干细胞及其衍生物与应用
|
|
CN114657135A
(zh)
*
|
2020-12-22 |
2022-06-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达Tim-3靶向抑制因子的多能干细胞及其衍生物与应用
|
|
US20240117002A1
(en)
*
|
2020-12-23 |
2024-04-11 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2022137181A1
(en)
*
|
2020-12-23 |
2022-06-30 |
Crispr Therapeutics Ag |
Co-use of lenalidomide with car-t cells
|
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
|
WO2022144855A1
(en)
|
2020-12-31 |
2022-07-07 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
CA3204417A1
(en)
*
|
2021-01-29 |
2022-08-04 |
Allogene Therapeutics, Inc. |
Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
|
|
EP4288072A4
(en)
*
|
2021-02-02 |
2025-10-08 |
Carisma Therapeutics Inc |
SELF-POLARIZING IMMUNE CELLS
|
|
AU2022228364A1
(en)
*
|
2021-03-05 |
2023-09-14 |
Factor Bioscience Inc. |
Engineered immune cell therapies
|
|
BR112023018844A2
(pt)
*
|
2021-04-07 |
2023-10-10 |
Century Therapeutics Inc |
Composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidas
|
|
US20240226164A1
(en)
*
|
2021-05-27 |
2024-07-11 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
WO2022269393A1
(en)
*
|
2021-06-23 |
2022-12-29 |
Crispr Therapeutics Ag |
Engineered cells with improved protection from natural killer cell killing
|
|
JP2024529494A
(ja)
*
|
2021-07-30 |
2024-08-06 |
クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド |
抗原ターゲティング、抗ｃｄ１６ａおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用
|
|
WO2023019185A1
(en)
*
|
2021-08-10 |
2023-02-16 |
Gentibio, Inc. |
Compositions and methods for engineering stable tregs
|
|
CN114107378A
(zh)
*
|
2021-09-13 |
2022-03-01 |
钦元再生医学(珠海)有限公司 |
一种通用型car-t细胞的制备方法
|
|
IL312565A
(en)
*
|
2021-11-08 |
2024-07-01 |
Fate Therapeutics Inc |
Engineered effector cells for trafficking of allogeneic cell therapies in solid tumors
|
|
CN116103239A
(zh)
*
|
2021-11-11 |
2023-05-12 |
南京北恒生物科技有限公司 |
工程化免疫细胞及其用途
|
|
EP4445136A4
(en)
*
|
2021-12-06 |
2025-12-31 |
Wuxi Biologics Ireland Ltd |
3D BIOASSESSMENTS FOR ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY MEASUREMENT
|
|
CN114414541A
(zh)
*
|
2021-12-17 |
2022-04-29 |
上海药明生物医药有限公司 |
一种应用3d细胞成像分析系统检测t细胞杀伤效力的方法
|
|
JP2025501617A
(ja)
*
|
2021-12-24 |
2025-01-22 |
ヘマセル バイオテクノロジー インコーポレイテッド |
相同組換え及びインテグラーゼ媒介性組換えによりヒト人工多能性幹細胞を製造する方法
|
|
CN114317607B
(zh)
*
|
2021-12-31 |
2024-08-02 |
苏州桑尼赛尔生物医药有限公司 |
融合一代靶向cd7 car和二代靶向bcma的双靶点通用car-t细胞及制备方法
|
|
WO2023182861A1
(ko)
*
|
2022-03-25 |
2023-09-28 |
에이치케이이노엔 주식회사 |
항-hla-g 키메라 항원 수용체 및 이의 용도
|
|
US20250222029A1
(en)
|
2022-04-08 |
2025-07-10 |
Fate Therapeutics, Inc. |
Chimeric antigen receptor for tumor targeting
|
|
US20250228943A1
(en)
|
2022-04-08 |
2025-07-17 |
Fate Therapeutics, Inc. |
Cells having solid tumor targeting backbone and use thereof
|
|
CN116948012B
(zh)
*
|
2022-04-13 |
2024-07-26 |
星奕昂(上海)生物科技有限公司 |
增强细胞功能的cd16抗剪切突变体
|
|
CN114478806B
(zh)
*
|
2022-04-14 |
2022-07-01 |
呈诺再生医学科技(北京)有限公司 |
一种提升免疫细胞杀伤活性的嵌合受体及其应用
|
|
KR20250022772A
(ko)
|
2022-06-09 |
2025-02-17 |
우모자 바이오파마 인코포레이티드 |
Nk 세포 분화를 위한 조성물 및 방법
|
|
EP4299734A1
(en)
*
|
2022-07-01 |
2024-01-03 |
ETH Zurich |
Cell line for discovering tcr antigens and uses thereof
|
|
AU2023314782A1
(en)
|
2022-07-27 |
2025-01-30 |
Umoja Biopharma, Inc. |
Differentiation of stem cells in suspension culture
|
|
CN116042527B
(zh)
*
|
2022-09-07 |
2023-08-22 |
广州瑞臻再生医学科技有限公司 |
一种促进NK细胞分化的iPS细胞系及其构建方法与应用
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
CN116445414B
(zh)
*
|
2023-03-03 |
2025-07-08 |
广州瑞臻再生医学科技有限公司 |
基因修饰多潜能干细胞衍生的增强型nk细胞的方法及其应用
|
|
CN116410336B
(zh)
*
|
2023-06-02 |
2023-09-22 |
云南赛元生物技术有限公司 |
一种嵌合抗原受体的编码核苷酸、car-nk细胞及其构建方法和应用
|
|
WO2025146467A1
(en)
|
2024-01-04 |
2025-07-10 |
Onk Therapeutics Limited |
Targeted il-15 construct delivery
|
|
WO2025158400A1
(en)
*
|
2024-01-24 |
2025-07-31 |
Yale University |
Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy
|
|
CN117946973B
(zh)
*
|
2024-03-26 |
2024-05-28 |
苏州艾凯利元生物科技有限公司 |
一种CAR-iNK细胞及其制备方法与应用
|